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Abstract 
Spinal arterial vascularization is supplied by a large anastomotic net, making spinal 
ischemic events far less common than ischemic cerebral strokes. Polycythemia vera, due 
to blood hyperviscosity and activated platelet aggregation, is associated with a higher 
risk of arterial and venous thrombotic events. We report a patient with spinal cord 
transient ischemic attacks, a rarely presenting manifestation, and polycythemia vera, 
which highlights the thrombotic potential of this disease, and the requirement of 
exhaustive diagnostic workout of a spinal ischemic event. 
 
Introduction 
Spinal arterial vascularization is supplied by a large anastomotic net, making spinal 
ischemic events far less common than ischemic cerebral strokes. Preobrashenski was the 
first to describe the anterior spinal artery syndrome in 1904, following Bastian’s 
suggestion in 1882 that spinal cord softening might be the result of vascular occlusion [1]. 
Usually the causes of spinal ischemic events are: aortic or vertebral artery disease, 
resulting from atherosclerosis, embolic infarction or dissecting aneurism; 
compression/trauma; iatrogenic, following a number of surgical and diagnostic 
procedures; and less frequently, systemic diseases such as vasculitis or severe systemic 
hypotension. Prognosis of spinal cord infarct has not been completely determined, since, 
given its low frequency, the number of cases have been too small to define broadly the 
natural history of the disease [2]. Case Rep Neurol 2011;3:284–288 
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We describe a case of transient spinal cord ischemia as a presenting manifestation of 
polycythemia vera, which is a rare hematologic disease associated with blood 
hyperviscosity and higher risk of thrombotic events. 
Case Report 
A 52-year-old male, Caucasian, with previous nephrolithiasis and a transient lower limbs motor 
deficit without medical investigation 12 years ago, presented, after physical effort, an acute low back 
pain without irradiation, with motor deficit in the lower limbs with no sensibility or sphincterian 
dysfunction. Initial neurologic examination disclosed proximal paraparesis with abolished myotatic and 
plantar reflexes, bilaterally. Spontaneous clinical recovery was observed, and 24 h later, only left lower 
limb hyperactive myotatic reflexes were present. Five months later, a new episode with identical 
symptoms occurred, resolving in 30 min, with a normal neurologic examination on arrival at emergency 
room. 
Initial laboratory evaluation showed only high erythrocyte and platelet counts, with increased 
hemoglobin and hematocrit. Posterior exhaustive laboratory investigation excluded vasculitis, collagen 
and coagulation disorders and finally infectious diseases such as syphilis, human immunodeficiency 
virus and Epstein-Barr virus (table 1). The thoracic-abdomino-pelvic CT (with angio CT) scan showed 
a splenomegaly with no signs of aortic dissection. Lumbar puncture, brain CT scan, spinal MRI, 
somatosensitive evoked potentials and electromyogram were normal. A spinal angiography was 
performed, showing artery of Adamkiewicz origin at the T11 level, with no ascending branch (fig. 1). 
Diagnosis of polycythemia vera was confirmed after bone marrow biopsy and myelogram, low levels 
of erythropoietin and positive JAK2 V617F mutation. He was treated with phlebotomies, first biweekly 
then monthly, hydroxyurea and a platelet inhibitor. In a follow-up time of two years, no new neurologic 
symptoms relapsed since treatment was started. 
Discussion 
Polycythemia vera is a chronic myeloproliferative neoplasm, characterized by 
overproduction of mature blood elements with predominance of erythroid lineage, 
variable degree of bone marrow fibrosis and extramedullary hematopoiesis (in spleen and 
liver) typical of more advanced phases of the disease. In 2005 the first molecular 
abnormality, represented by a point mutation in JAK2 exon 14, was identified, leading to 
revision of WHO diagnostic criteria in 2008 [3]. This mutation is present in 95% of cases 
[4]. 
This disease is associated with a higher risk of arterial and venous thrombotic events, 
namely in the cerebral, ocular, coronary and pulmonary territories. In a large prospective 
cohort of 1,638 patients with polycythemia vera, the incidence of recurrent thrombosis 
was 5% patient-years among individuals <65 years old and 10.9% patient-years among 
those >65 years old [5]. In a recent survey from Italian GINEMA group, the calculated 
recurrence rate is 5.6% per patient-year, and the cumulative probability is 49.9% at 10 
years [6]. The first recurrent thrombosis involved arterial vessels in 60.8% of cases and 
venous vessels in 39.7% of cases. The overall probability of recurrence was not predicted 
by whether the first manifestation was in the arterial or venous district, but re-thrombosis 
occurred preferentially in the same vascular district previously affected [5, 6]. 
Nevertheless, the mechanisms finally responsible for the increased thrombotic 
tendency have not been clearly elucidated, although risk factors for thrombosis have been 
identified and are currently employed for stratifying patients to appropriate therapeutic Case Rep Neurol 2011;3:284–288 
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options. The two most important thrombotic risk factors are advanced age (>60 years) 
and prior history of thrombosis [6]. Abnormalities of blood cells, activation of 
neutrophils and platelets, and a hypercoagulability state, can all act in conjunction to lead 
to thrombosis [4, 7]. Intriguing data also point to the JAK2 V617F mutation as both a 
marker and a mechanism for thrombosis, besides a diagnostic tool, further raising the risk 
of thrombosis in younger patients [4]. 
Current treatment of this disease is mainly aimed at preventing major cardiovascular 
events and is based on the risk category to which the patient belongs. For low-risk 
patients (<60 years old and no previous thrombosis), phlebotomies and platelet 
inhibitors, whereas for high-risk patients (>60 years old and/or previous thrombosis), 
cytotoxic therapy should also be instituted. 
We report a patient with spinal cord transient ischemic attacks, a rarely presenting 
manifestation, which highlights the thrombotic potential of this disease. The anatomy of 
spinal cord blood supply is complicated by individual variations in the number, size and 
location of its vasculature [8]. However, certain features are relatively consistent and of 
clinical importance. There are 31 pairs of radicular arteries that enter the vertebral canal 
through the intervertebral foramen, but the majority of these arteries regress during 
development, leaving only four to eight contributors, termed radiculomedullary arteries. 
The largest and most constant radicular artery is the arteria radicularis magna or artery of 
Adamkiewicz, which usually arises from level T9 to T12. The midthoracic region has 
fewer arteries per cm of spinal cord than any other spinal cord region, making this region 
particularly vulnerable to ischemia during global hypoperfusion, especially T4 to T8 
spinal cord levels. 
The origin of artery of Adamkiewicz at T11 level, with no ascending branch, as seen in 
our patient’s spinal angiography, was interpreted as an anatomical variation that 
predisposed to several spinal cord transient attacks. Since he was a high-risk patient 
because of recurrent thrombosis, cytotoxic therapy besides platelet inhibitors and 
phlebotomies was instituted, with good clinical response. Recently, patients carrying 
acquired JAK2 V617F mutation, as this patient, have been demonstrated to obtain better 
cytoreduction and have a lower rate of arterial thrombosis when treated with hydroxyurea 
[9]. 
In conclusion, this case report supports the knowledge that acute nontraumatic 
complete or partial
 transverse myelopathies as well as classic vascular spinal cord 
syndromes are etiologically ambiguous and require well-established diagnostic 
procedures such as exhaustive blood evaluation, lumbar puncture, neuroimaging as spinal 
MRI, as well as thoracic-abdomino-pelvic CT (with angio CT), and eventually a spinal 
angiography [10, 11]. Polycythemia vera, although a rare hematological disease, has to be 
considered as a possible cause of ischemic events in cerebral or spinal territories, when 
other more frequent etiologies are excluded. 
Finally, this case holds up JAK2 mutation as a novel disease-associated risk factor, 
useful for predicting cardiovascular complications of polycythemia vera [12]. 
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Table 1. Laboratory evaluation 
Blood Results  at 
baseline 
Results after  
6 months of  
treatment 
Reference 
values 
Hg, g/dl  20.1 Ĺ 17.4  13–18 
Hematocrit, %  59.3 Ĺ 53.3  40–54 
Leukocytes, Pl 9,100  7,800  4,000–11,000 
Platelets, Pl 613,000  Ĺ 570,000  Ĺ 150–400,000 
ESR, mm  1  1  <13 
CRP, mg/dl  0.42  0.07  <1 
ANA/Anti DNA ds  Neg/Neg  –  – 
Anti SSA/SSB  Neg/Neg  –  – 
HIV 1 e 2/VDRL  Neg  –  – 
β2-Microglobulin, mg/l  2.28  1.31  0.67–1.3 
Erythropoietin, mU/l  1.52 Ļ –  2.6–34 
Hg = Hemoglobin; ESR = erythrocyte sedimentation rate; CRP = C 
reactive protein. 
 
 
 
 
 
Fig. 1. Spinal angiography showed origin of artery of Adamkiewicz at the T11 level, with no ascending 
branch. 
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